Patient Name : MR.

SAMBIT SAHA Other Referral: DIRECT

Age / Gender : 41 years / Male Billing Time : Oct 11, 2024, 10:54 a.m.
Patient ID : 139803 Collection Time : Oct 11, 2024, 10:54 a.m.
Source : DIRECT Reporting Time : Oct 11, 2024, 05:54 p.m.
Referral : SELF Sample ID :
013528524

Test Description Value(s) Reference Range Unit(s)

Hemoglobin (Hb)* 14.9 13.5 - 18.0 gm/dL

Method : Cynmeth Photometric Measurement
Erythrocyte (RBC) Count* 4.74 4.7 - 6.0 mil/cu.mm
Method : Electrical Impedence
Packed Cell Volume (PCV)* 41.8 42 - 52 %
Method : Calculated
Mean Cell Volume (MCV)* 88.19 78 - 100 fL
Method : Electrical Impedence
Mean Cell Haemoglobin (MCH)* 31.43 27 - 31 pg
Method : Calculated
Mean Corpuscular Hb Concn. (MCHC)* 35.65 32 - 36 gm/dL
Method : Calculated
Red Cell Distribution Width (RDW)* 13.7 11.5 - 14.0 %
Method : Electrical Impedence
Total Leucocytes (WBC) Count* 6590 4000-11000 cell/cu.mm
Method : Electrical Impedence
Neutrophils* 55.5 40 - 80 %
Method : VCSn Technology
Lymphocytes*1 35.6 20 - 40 %
Method : VCSn Technology
Monocytes* 6.1 2 - 10 %
Method : VCSn Technology
Eosinophils* 2.8 1-6 %
Method : VCSn Technology
Basophils* 00 1-2 %
Method : VCSn Technology
Absolute Neutrophil Count* 3660 2000 - 7000 cells/c.mm
Method : Calculated
Absolute Lymphocyte Count* 2350 1000 - 3000 cells/c.mm
Method : Calculated
Absolute Monocyte Count* 400 200 - 1000 cells/c.mm
Method : Calculated
Absolute Eosinophil Count* 180 20 - 500 cells/c.mm
Method : Calculated
Platelet Count* 235 150 - 450 10^3/ul
Method : Electrical Impedence
Mean Platelet Volume (MPV)* 10.5 7.2 - 11.7 fL
Method : Electrical Impedence
PCT* 0.250 0.220 - 0.300 %
Method : Calculated
PDW* 16.7 9.0 - 17.0 %
Method : Calculated

Page 1 of 5
 Patient Name : MR. SAMBIT SAHA Other Referral: DIRECT
Age / Gender : 41 years / Male Billing Time : Oct 11, 2024, 10:54 a.m.
Patient ID : 139803 Collection Time : Oct 11, 2024, 10:54 a.m.
Source : DIRECT Reporting Time : Oct 11, 2024, 05:54 p.m.
Referral : SELF Sample ID :
013528524

Test Description Value(s) Reference Range Unit(s)

Tests done on Automated Five Part Cell Counter. (WBC, RBC,Platelet count by impedance method, colorimetric method for Hemoglobin, WBC differential by flow cytometry using

laser technology other parameters are calculated). All Abnormal Haemograms are reviewed confirmed microscopically.

Bilirubin - Total 0.45 0.3 - 1.2 mg/dL

Method : Serum, Jendrassik Grof
Bilirubin - Direct 0.15 Adults and Children: < 0.2 mg/dL
Method : Serum, Diazotization
Bilirubin - Indirect 0.30 0.1 - 1.0 mg/dL
Method : Serum, Calculated
SGOT (AST) 50.00 < 50 U/L
Method : Serum, UV with P5P, IFCC 37 degree
SGPT (ALT) 85.00 < 50 U/L
Method : Serum, UV with P5P, IFCC 37 degree
Alkaline Phosphatase-ALPI 110.00 30-120 U/L
Method : Serum, PNPP, AMP Buffer, IFCC 37 degree
Total Protein 7.60 6.6 - 8.3 g/dL
Method : Serum, Biuret, reagent blank end point
Albumin 4.30 Adults: 3.5 - 5.2 g/dL
Method : Serum, Bromcresol purple
Globulin 3.30 1.8 - 3.6 g/dL
Method : Calculated
A/G Ratio 1.30 1.2 - 2.2 ratio
Method : Calculated
GGT-Gamma Glutamyl Transpeptidase 120.40 11 -55 U/L
Method : Method : Serum, G-glutamyl-carboxy-nitroanilide

Urea * 19.00 15 - 45 mg/dL

Method : Serum
Blood Urea Nitrogen-BUN* 8.88 7 - 18 mg/dL
Method : Serum, Urease
Creatinine* 1.07 0.60 - 1.30 mg/dL
Method : Serum, Jaffe IDMS
Sodium* 141 135 - 155 mmol/L
Method : Serum, Indirect ISE
Potassium* 4.0 3.5 - 5.5 mmol/L
Method : Serum, Indirect ISE
Chloride* 102 96 - 106 mmol/L
Method : Serum, Indirect ISE

Page 2 of 5
 Patient Name : MR. SAMBIT SAHA Other Referral: DIRECT
Age / Gender : 41 years / Male Billing Time : Oct 11, 2024, 10:54 a.m.
Patient ID : 139803 Collection Time : Oct 11, 2024, 10:54 a.m.
Source : DIRECT Reporting Time : Oct 11, 2024, 05:54 p.m.
Referral : SELF Sample ID :
013528524

Test Description Value(s) Reference Range Unit(s)

Cholesterol-Total 223.00 Desirable: <= 200 mg/dL

Method : Serum, Cholesterol oxidase esterase, peroxidase Borderline High: 201-239
High: > 239
Ref: The National Cholesterol
Education Program (NCEP) Adult
Treatment Panel III Report.
Triglycerides 238.00 Normal: < 150 mg/dL
Method : Serum, Enzymatic, endpoint Borderline High: 150-199
High: 200-499
Very High: >= 500
Cholesterol-HDL Direct 52.50 Normal: > 40 mg/dL
Method : Serum, Direct measure-PEG Major Heart Risk: < 40
LDL Cholesterol 122.90 Optimal: < 100 mg/dL
Method : Serum Near optimal/above optimal: 100-129
Borderline high: 130-159
High: 160-189
Very High: >= 190
Non - HDL Cholesterol, Serum 170.50 Desirable: < 130 mg/dL mg/dL
Method : calculated Borderline High: 130-159mg/dL
High: 160-189 mg/dL
Very High: > or = 190 mg/dL
VLDL Cholesterol 47.60 6 - 38 mg/dL
Method : calculated
CHOL/HDL RATIO 4.25 3.5 - 5.0 ratio
Method : calculated
LDL/HDL RATIO 2.34 Desirable / low risk - 0.5 -3.0 ratio
Method : calculated Low/ Moderate risk - 3.0- 6.0
Elevated / High risk - > 6.0
HDL/LDL RATIO 0.43 Desirable / low risk - 0.5 -3.0 ratio
Method : calculated Low/ Moderate risk - 3.0- 6.0
Elevated / High risk - > 6.0

Note: 8-10 hours fasting sample is required.

Glyco Hb (HbA1C) 5.8 Non-Diabetic: <=5.6 %

Method : EDTA Whole blood,HPLC Pre Diabetic:5.7-6.4
Diabetic: >=6.5
Estimated Average Glucose : 119.76 - <140 mg/dL
Interpretations

Page 3 of 5
 Patient Name : MR. SAMBIT SAHA Other Referral: DIRECT
Age / Gender : 41 years / Male Billing Time : Oct 11, 2024, 10:54 a.m.
Patient ID : 139803 Collection Time : Oct 11, 2024, 10:54 a.m.
Source : DIRECT Reporting Time : Oct 11, 2024, 05:54 p.m.
Referral : SELF Sample ID :
013528524

Test Description Value(s) Reference Range Unit(s)

1. HbA1C has been endorsed by clinical groups and American Diabetes Association guidelines 2017 for diagnosing diabetes using a
cut off point of 6.5%
2. Low glycated haemoglobin in a non diabetic individual are often associated with systemic inflammatory diseases, chronic anaemia
(especially severe iron deficiency and haemolytic), chronic renal failure and liver diseases. Clinical correlation suggested.
3. In known diabetic patients, following values can be considered as a tool for monitoring the glycemic control.
Excellent control-6-7 %
Fair to Good control – 7-8 %
Unsatisfactory control – 8 to 10 %
Poor Control – More than 10 %

Glucose Random* 92.00 70.00 - 140.00 mg/dL

Method : GOD/POD

Total T3* 1.32 0.87 - 1.78 ng/ml

Method : Serum,CLIA

TSH 2.66 1- 4 Days after birth - 0.8 - 6.9 µIU/mL µIU/mL

Method : CLIA 4 Days after birth - 1.3 - 16 µIU/mL
1- 11 Months - 0.9 - 7.7 µIU/mL
Adults - 0.38 - 5.33 µIU/mL

1. Serum TSH concentrations exhibit a diurnal variation with the peak occurring during the night.

2. Useful for:Screening for thyroid dysfunction and detecting mild (subclinical), as well as overt, primary hypo- or hyperthyroidism in
ambulatory patients.
3. Monitoring patients on thyroid replacement therapy.
4. Confirmation of thyroid-stimulating hormone (TSH) suppression in thyroid cancer patients on thyroxine suppression therapy.
5.Prediction of thyrotropin-releasing hormone-stimulated TSH response.

Total T4 8.88 4.61 - 14.94 µg/dL

Method : Serum,CLIA

**END OF REPORT**

Page 4 of 5
 Patient Name : MR. SAMBIT SAHA Other Referral: DIRECT
Age / Gender : 41 years / Male Billing Time : Oct 11, 2024, 10:54 a.m.
Patient ID : 139803 Collection Time : Oct 11, 2024, 10:54 a.m.
Source : DIRECT Reporting Time : Oct 11, 2024, 05:54 p.m.
Referral : SELF Sample ID :
013528524

Test Description Value(s) Reference Range Unit(s)

Page 5 of 5